Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer

December 8th 2017

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

No Difference in Overall Survival with Shorter Extended AI Therapy

December 7th 2017

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.

Acupuncture Reduces AI-Associated Joint Pain in Women with Breast Cancer

December 7th 2017

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer

December 7th 2017

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

GnRHa May Protect Ovarian Function, Preserve Fertility in Premenopausal Women With Early-Stage Breast Cancer

December 7th 2017

Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.

Dr. Coombes on Intriguing Results With Celecoxib in Breast Cancer

December 7th 2017

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer

December 7th 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer

December 7th 2017

Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Dr. Nangia Discusses the Logistics of Implementing a Scalp Cooling System

December 7th 2017

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.

Pembrolizumab/Trastuzumab Active in HER2-Positive Breast Cancer

December 7th 2017

The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.

Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes

December 6th 2017

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

Sacituzumab Govitecan Highly Effective in Heavily Pretreated mTNBC

December 6th 2017

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

Rugo Covers Scope of Recent Breast Cancer Advances

December 6th 2017

Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.

Role of Neoadjuvant Chemotherapy Evolving in TNBC

December 4th 2017

Melanie Majure, MD, discusses the optimal role chemotherapy for patients with TNBC and the importance of achieving a pCR.

FDA Approves Trastuzumab Biosimilar

December 1st 2017

The FDA has approved the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which now has has approved indications for HER2-positive patients with breast or metastatic gastric or gastroesophageal junction adenocarcinoma.

Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

November 29th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Expert Emphasizes Importance of Neoadjuvant Therapy in HER2+ Breast Cancer

November 29th 2017

Patrick Borgen, MD, discusses the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

November 28th 2017

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Adjuvant Treatment Evolving for HER2+ Breast Cancer

November 27th 2017

Sara M. Tolaney, MD, discusses the state of adjuvant treatment for patients with HER2-positive breast cancer.

Expert Highlights Expanding Options for HER2+ Breast Cancer

November 27th 2017

Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.